Ischemia Biomarker Now on Modular System

An albumin cobalt-binding (ACB) test for the detection of ischemia modified albumin (IMA) is now available on a modular analytic system.

IMA is a serum biomarker that assists in the early evaluation of acute coronary syndrome (ACS) prior to heart attack in patients presenting to hospital emergency departments with chest pain suggestive of cardiac origin. When IMA was cleared by the U.S. Food and Drug Administration (FDA) in July 2003, the agency noted that "The test is the first new blood test for evaluation of heart attacks since the introduction of the blood test for troponin…in 1994.”

IMA is produced when albumin circulating in blood comes in contact with ischemic tissue in the heart or other organ. During ischemia, a series of chemical reactions occur that modify albumin, resulting in ischemia modified albumin. IMA can help emergency doctors identify candidates for early discharge, saving time and money for the healthcare system. The test was developed by Ischemia Technologies, Inc. (Denver, CO, USA) and is available on the Modular Analytics P clinical chemistry module of Roche Diagnostics (Basel, Swizerland).

The Modular Analytics P, used widely in hospital laboratories throughout the world, is part of a fully automated system used by diagnostic laboratories to manage high throughput workloads for a large variety of blood tests.





Related Links:
Roche Diagnostics
Ischemia Techologies